These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 19690192)

  • 1. Gene expression profiling of bone marrow endothelial cells in patients with multiple myeloma.
    Ria R; Todoerti K; Berardi S; Coluccia AM; De Luisi A; Mattioli M; Ronchetti D; Morabito F; Guarini A; Petrucci MT; Dammacco F; Ribatti D; Neri A; Vacca A
    Clin Cancer Res; 2009 Sep; 15(17):5369-78. PubMed ID: 19690192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myeloma.
    De Luisi A; Ferrucci A; Coluccia AM; Ria R; Moschetta M; de Luca E; Pieroni L; Maffia M; Urbani A; Di Pietro G; Guarini A; Ranieri G; Ditonno P; Berardi S; Caivano A; Basile A; Cascavilla N; Capalbo S; Quarta G; Dammacco F; Ribatti D; Vacca A
    Clin Cancer Res; 2011 Apr; 17(7):1935-46. PubMed ID: 21307145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different Adaptive Responses to Hypoxia in Normal and Multiple Myeloma Endothelial Cells.
    Filippi I; Saltarella I; Aldinucci C; Carraro F; Ria R; Vacca A; Naldini A
    Cell Physiol Biochem; 2018; 46(1):203-212. PubMed ID: 29587264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A HGF/cMET autocrine loop is operative in multiple myeloma bone marrow endothelial cells and may represent a novel therapeutic target.
    Ferrucci A; Moschetta M; Frassanito MA; Berardi S; Catacchio I; Ria R; Racanelli V; Caivano A; Solimando AG; Vergara D; Maffia M; Latorre D; Rizzello A; Zito A; Ditonno P; Maiorano E; Ribatti D; Vacca A
    Clin Cancer Res; 2014 Nov; 20(22):5796-807. PubMed ID: 25212607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Four proteins governing overangiogenic endothelial cell phenotype in patients with multiple myeloma are plausible therapeutic targets.
    Berardi S; Caivano A; Ria R; Nico B; Savino R; Terracciano R; De Tullio G; Ferrucci A; De Luisi A; Moschetta M; Mangialardi G; Catacchio I; Basile A; Guarini A; Zito A; Ditonno P; Musto P; Dammacco F; Ribatti D; Vacca A
    Oncogene; 2012 May; 31(18):2258-69. PubMed ID: 21963844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone marrow fibroblasts overexpress miR-27b and miR-214 in step with multiple myeloma progression, dependent on tumour cell-derived exosomes.
    Frassanito MA; Desantis V; Di Marzo L; Craparotta I; Beltrame L; Marchini S; Annese T; Visino F; Arciuli M; Saltarella I; Lamanuzzi A; Solimando AG; Nico B; De Angelis M; Racanelli V; Mariggiò MA; Chiacchio R; Pizzuti M; Gallone A; Fumarulo R; D'Incalci M; Vacca A
    J Pathol; 2019 Feb; 247(2):241-253. PubMed ID: 30357841
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Bolzoni M; Ronchetti D; Storti P; Donofrio G; Marchica V; Costa F; Agnelli L; Toscani D; Vescovini R; Todoerti K; Bonomini S; Sammarelli G; Vecchi A; Guasco D; Accardi F; Palma BD; Gamberi B; Ferrari C; Neri A; Aversa F; Giuliani N
    Haematologica; 2017 Apr; 102(4):773-784. PubMed ID: 28057743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The imbalance between Survivin and Bim mediates tumour growth and correlates with poor survival in patients with multiple myeloma.
    Romagnoli M; Séveno C; Wuillème-Toumi S; Amiot M; Bataille R; Minvielle S; Barillé-Nion S
    Br J Haematol; 2009 Apr; 145(2):180-9. PubMed ID: 19298592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of interleukin 16 in multiple myeloma.
    Atanackovic D; Hildebrandt Y; Templin J; Cao Y; Keller C; Panse J; Meyer S; Reinhard H; Bartels K; Lajmi N; Sezer O; Zander AR; Marx AH; Uhlig R; Zustin J; Bokemeyer C; Kröger N
    J Natl Cancer Inst; 2012 Jul; 104(13):1005-20. PubMed ID: 22745469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pentraxin 3 (PTX3) inhibits plasma cell/stromal cell cross-talk in the bone marrow of multiple myeloma patients.
    Basile A; Moschetta M; Ditonno P; Ria R; Marech I; De Luisi A; Berardi S; Frassanito MA; Angelucci E; Derudas D; Specchia G; Curci P; Pavone V; Rossini B; Ribatti D; Bottazzi B; Mantovani A; Presta M; Dammacco F; Vacca A
    J Pathol; 2013 Jan; 229(1):87-98. PubMed ID: 22847671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis.
    Pichiorri F; Suh SS; Ladetto M; Kuehl M; Palumbo T; Drandi D; Taccioli C; Zanesi N; Alder H; Hagan JP; Munker R; Volinia S; Boccadoro M; Garzon R; Palumbo A; Aqeilan RI; Croce CM
    Proc Natl Acad Sci U S A; 2008 Sep; 105(35):12885-90. PubMed ID: 18728182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical analysis of NOTCH1 and JAGGED1 expression in multiple myeloma and monoclonal gammopathy of undetermined significance.
    Skrtić A; Korać P; Krišto DR; Ajduković Stojisavljević R; Ivanković D; Dominis M
    Hum Pathol; 2010 Dec; 41(12):1702-10. PubMed ID: 20800871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression profile of telomere-associated genes in multiple myeloma.
    Díaz de la Guardia R; Catalina P; Panero J; Elosua C; Pulgarin A; López MB; Ayllón V; Ligero G; Slavutsky I; Leone PE
    J Cell Mol Med; 2012 Dec; 16(12):3009-21. PubMed ID: 22947336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIF-1α of bone marrow endothelial cells implies relapse and drug resistance in patients with multiple myeloma and may act as a therapeutic target.
    Ria R; Catacchio I; Berardi S; De Luisi A; Caivano A; Piccoli C; Ruggieri V; Frassanito MA; Ribatti D; Nico B; Annese T; Ruggieri S; Guarini A; Minoia C; Ditonno P; Angelucci E; Derudas D; Moschetta M; Dammacco F; Vacca A
    Clin Cancer Res; 2014 Feb; 20(4):847-58. PubMed ID: 24297864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell autonomous and microenvironmental regulation of tumor progression in precursor states of multiple myeloma.
    Manier S; Kawano Y; Bianchi G; Roccaro AM; Ghobrial IM
    Curr Opin Hematol; 2016 Jul; 23(4):426-33. PubMed ID: 27101529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The expression of osteopontin and vascular endothelial growth factor in correlation with angiogenesis in monoclonal gammopathy of undetermined significance and multiple myeloma.
    Babarović E; Valković T; Budisavljević I; Balen I; Štifter S; Duletić-Načinović A; Lučin K; Jonjić N
    Pathol Res Pract; 2016 Jun; 212(6):509-16. PubMed ID: 26997492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upregulation of Syndecan-1 in the bone marrow microenvironment in multiple myeloma is associated with angiogenesis.
    Andersen NF; Kristensen IB; Preiss BS; Christensen JH; Abildgaard N
    Eur J Haematol; 2015 Sep; 95(3):211-7. PubMed ID: 25353275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VEGF masks BNIP3-mediated apoptosis of hypoxic endothelial cells.
    Jurasz P; Yurkova N; Kirshenbaum L; Stewart DJ
    Angiogenesis; 2011 May; 14(2):199-207. PubMed ID: 21318419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells.
    Bolzoni M; Donofrio G; Storti P; Guasco D; Toscani D; Lazzaretti M; Bonomini S; Agnelli L; Capocefalo A; Dalla Palma B; Neri A; Nicolini F; Lisignoli G; Russo F; Colla S; Aversa F; Giuliani N
    Leukemia; 2013 Feb; 27(2):451-63. PubMed ID: 22781592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of erythropoietin in the angiogenic activity of bone marrow endothelial cells of MGUS and multiple myeloma patients.
    Lamanuzzi A; Saltarella I; Ferrucci A; Ria R; Ruggieri S; Racanelli V; Rao L; Annese T; Nico B; Vacca A; Ribatti D
    Oncotarget; 2016 Mar; 7(12):14510-21. PubMed ID: 26919105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.